Sana Biotechnology, Inc.
SANA
$1.76
-$0.01-0.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.87% | -26.75% | -0.75% | -2.96% | 42.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.78% | 1.26% | -52.22% | 34.03% | 20.86% |
| Operating Income | 32.78% | -1.26% | 52.22% | -34.03% | -20.86% |
| Income Before Tax | 44.31% | -6,189.84% | 55.88% | -30.87% | -9.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.31% | -6,189.84% | 55.88% | -30.87% | -9.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.31% | -6,189.84% | 55.88% | -30.87% | -9.54% |
| EBIT | 32.78% | -1.26% | 52.22% | -34.03% | -20.86% |
| EBITDA | 34.08% | -2.15% | 53.90% | -36.83% | -22.23% |
| EPS Basic | 53.49% | -5,190.00% | 63.77% | -15.16% | -5.70% |
| Normalized Basic EPS | 49.05% | 13.25% | 59.22% | -17.16% | -15.31% |
| EPS Diluted | 53.45% | -5,293.88% | 63.77% | -15.16% | -5.70% |
| Normalized Diluted EPS | 49.05% | 11.75% | 59.22% | -17.16% | -15.31% |
| Average Basic Shares Outstanding | 19.76% | 19.51% | 21.76% | 13.63% | 3.62% |
| Average Diluted Shares Outstanding | 19.76% | 17.43% | 21.76% | 13.63% | 3.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |